Summary of Significant Accounting Policies and Supplemental Balance Sheet Information (Tables)

12 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Amortized Cost, Unrealized Holding Gains (Losses) and Fair Value of Available for Sale Securities

As of September 30, 2023, the amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows. There were no available-for-sale securities as of September 30, 2022.

(In thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	3,936	$	—	$	(3	)	$	3,933
Available-for-sale securities	$	3,936	$	—	$	(3	)	$	3,933

Components of Inventories, net

Inventories, net of reserves of $1.8 million and $1.1 million as of September 30, 2023 and 2022, respectively, consisted of the following components:

	September 30,
(In thousands)	2023		2022
Raw materials	$	8,063	$	6,102
Work-in process		2,607		1,595
Finished products		4,169		4,122
Inventories, net	$	14,839	$	11,819

Summary of Prepaids and Other Current Assets

Prepaids and other current assets consisted of the following:

	September 30,
(In thousands)	2023		2022
Prepaid expenses	$	2,600	$	2,570
Irish research and development credits receivable		1,322		753
CARES Act employee retention credit receivable (1)		3,441		3,441
Prepaids and other	$	7,363	$	6,764

(1)Receivable consisted of anticipated reimbursement of personnel expenses incurred in fiscal periods prior to fiscal 2022 as a result of our eligibility for the employee retention credit under the provisions of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”).

Schedule of Property, Plant and Equipment

Property and equipment consisted of the following components:

	Useful Life	September 30,
(Dollars in thousands)	(Years)	2023			2022
Land	N/A	$	4,413		$	4,409
Laboratory fixtures and equipment	3 to 10		33,120			28,810
Buildings and improvements	3 to 20		26,964			26,373
Leasehold improvements	5 to 10		6,499			6,499
Office furniture and equipment	3 to 10		9,561			9,205
Construction-in-progress			1,936			3,175
Less: Accumulated depreciation			(56,467	)		(51,323	)
Property and equipment, net		$	26,026		$	27,148

Schedule of Intangible Assets

Intangible assets consisted of the following:

	September 30, 2023
(Dollars in thousands)	Weighted Average Original Life (Years)	Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships	9.3	$	11,260	$	(9,435	)	$	1,825
Developed technology	11.9		33,929		(11,048	)		22,881
Patents and other	14.9		2,338		(1,418	)		920
Total definite-lived intangible assets			47,527		(21,901	)		25,626
Unamortized intangible assets:
Trademarks and trade names			580		—			580
Intangible assets, net		$	48,107	$	(21,901	)	$	26,206

	September 30, 2022
(Dollars in thousands)	Weighted Average Original Life (Years)	Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships	9.3	$	10,454	$	(7,927	)	$	2,527
Developed technology	11.9		31,943		(7,994	)		23,949
Patents and other	14.9		2,338		(1,249	)		1,089
Total definite-lived intangible assets			44,735		(17,170	)		27,565
Unamortized intangible assets:
Trademarks and trade names			580		—			580
Intangible assets, net		$	45,315	$	(17,170	)	$	28,145

Estimated Amortization Expense

Based on the intangible assets in service as of September 30, 2023, estimated amortization expense for future fiscal years is as follows:

(In thousands)
2024	$	3,691
2025		3,656
2026		2,780
2027		2,534
2028		2,524
Thereafter		10,441
Definite-lived intangible assets	$	25,626

Schedule of Carrying Amount of Goodwill By Reportable Segment

Changes in the carrying amount of goodwill by segment were as follows:

(In thousands)	In Vitro Diagnostics		Medical Device			Total
Goodwill as of September 30, 2021	$	8,010	$	37,596		$	45,606
Foreign currency translation adjustment		—		(5,173	)		(5,173	)
Measurement period adjustments (1)		—		277			277
Goodwill as of September 30, 2022		8,010		32,700			40,710
Foreign currency translation adjustment		—		2,236			2,236
Goodwill as of September 30, 2023	$	8,010	$	34,936		$	42,946

(1)In fiscal 2022, measurement period adjustments were recorded to finalize the allocation of purchase consideration for the fiscal 2021 Vetex acquisition (Note 13).

Summary of Other Noncurrent Assets

Other noncurrent assets consisted of the following:

	September 30,
(In thousands)	2023		2022
Operating lease right-of-use assets	$	2,987	$	3,633
Other		877		1,136
Other assets, noncurrent	$	3,864	$	4,769

Schedule of Accrued Other Liabilities

Accrued other liabilities consisted of the following:

	September 30,
(In thousands)	2023		2022
Accrued professional fees	$	178	$	279
Accrued clinical study expense		1,056		1,425
Accrued purchases		1,142		1,655
Deferred consideration (1)		2,661		981
Operating lease liability, current portion		872		963
Other		535		551
Accrued other liabilities	$	6,444	$	5,854

(1)Deferred consideration consisted of the present value of guaranteed payments to be made in connection with the fiscal 2021 Vetex acquisition (Note 13) and with an asset acquisition in fiscal 2019 (Note 11).

Schedule of Other Long-term Liabilities

Other long-term liabilities consisted of the following:

	September 30,
(In thousands)	2023		2022
Deferred consideration (1)	$	1,754	$	4,260
Contingent consideration (2)		—		829
Unrecognized tax benefits (3)		3,332		1,841
Operating lease liabilities (4)		2,974		3,843
Other long-term liabilities	$	8,060	$	10,773

(1)Deferred consideration consisted of the present value of a guaranteed payment to be made in connection with the fiscal 2021 Vetex acquisition (Note 13).

(2)Contingent consideration consisted of the fair value of contingent consideration liabilities associated with the fiscal 2021 Vetex acquisition (Note 5 and Note 13).

(3)Unrecognized tax benefits (Note 9) included accrued interest and penalties, if applicable.

(4)Operating lease liabilities consisted of the non-current portion of the net present value of future minimum lease payments, reduced by the discounted value of leasehold improvement incentives paid or payable to the Company.

Schedule of Operating Lease Maturities

As of September 30, 2023, operating lease maturities were as follows:

(In thousands)
2024	$	1,217
2025		1,214
2026		1,132
2027		1,135
2028		574
Total expected operating lease payments		5,272
Less: Imputed interest		(1,426	)
Total operating lease liabilities	$	3,846

Denominator for Computation of Diluted Weighted Average Shares Outstanding

The following table presents the denominator for the computation of diluted weighted average shares outstanding:

	Fiscal Year
(In thousands)	2023		2022		2021
Basic weighted average shares outstanding		14,031		13,916		13,765
Dilutive effect of outstanding stock options, non-vested restricted stock, and non-vested restricted stock units		—		—		224
Diluted weighted average shares outstanding		14,031		13,916		13,989